Antihelminthics Market Size, Share, Growth, and Industry Analysis, Types (Benzimidazoles, Abamectin, Salicylanilides, Praziquantel, Other), Applications (Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis, Other), and Regional Insights and Forecast to 2035

Antihelminthics Market Size

Global Antihelminthics Market size was USD 1.97 Billion in 2025 and is projected to touch USD 2.14 Billion in 2026, rise to USD 2.31 Billion in 2027, and reach USD 4.38 Billion by 2035, exhibiting a CAGR of 8.3% during the forecast period (2026-2035). Market expansion is supported by preventive deworming campaigns, livestock health demand, pet care spending, and wider access to affordable generic medicines worldwide.

US Antihelminthics Market growth remains stable through companion animal healthcare, livestock management, and travel-related treatment needs. The United States contributes nearly 76% of North American demand. Around 43% of domestic purchases come from veterinary channels, while 24% come from retail and hospital pharmacy sales for human treatment needs.

Key Findings

• Market Size: Valued at $1.97 Billion in 2025, projected to touch $2.14 Billion in 2026, $2.31 Billion in 2027 and $4.38 Billion by 2035 at a CAGR of 8.3%.
• Growth Drivers: 51% livestock demand, 46% health campaigns, 38% pet care growth, 31% clinic stocking expansion.
• Trends: 41% easy-dose formats, 33% pediatric focus, 28% combination therapy, 26% long-shelf packaging.
• Key Players: Sanofi, Bayer, Abbott, Merck & Co., Pfizer & more.
• Regional Insights: Asia-Pacific 40%, North America 22%, Europe 20%, Middle East & Africa 18%, led by treatment volume and animal health demand.
• Challenges: 33% supply gaps, 29% resistance concerns, 26% rural delays, 22% adherence issues.
• Industry Impact: 44% generic expansion, 36% veterinary focus, 31% procurement support, 27% pet care growth.
• Recent Developments: 24% wider supply, 21% output gains, 19% pediatric acceptance, 18% coverage growth, 16% dosing accuracy.

A unique feature of the Antihelminthics Market is that demand often comes from both healthcare and agriculture at the same time. Around 35% of total treatment volumes are linked to veterinary use, making this market less dependent on one customer group than many other pharmaceutical categories.

Antihelminthics Market Trends

The Antihelminthics Market is growing steadily as public health systems, livestock programs, and routine deworming campaigns continue to expand across many regions. Around 62% of preventive parasite control programs in high-risk areas now include scheduled antihelminthic treatment cycles. Nearly 48% of primary healthcare centers in rural zones keep at least one broad-spectrum antihelminthic medicine in regular stock. About 44% of veterinary parasite treatment demand is linked to livestock productivity improvement, especially in cattle, poultry, and sheep farming. School-based deworming programs account for close to 37% of community treatment volumes in several developing economies. Praziquantel and benzimidazole classes remain widely used, with nearly 53% combined share in many mass treatment settings. Asia-Pacific represents about 39% of total demand because of large population size and tropical disease burden. Africa also remains important, supported by parasite control initiatives and sanitation improvement programs. Around 31% of manufacturers are focusing on chewable tablets, flavored suspensions, and easier pediatric dosing formats. The Antihelminthics Market is also seeing stronger demand from companion animal care, where nearly 27% of pet owners now use routine deworming schedules.

Antihelminthics Market Dynamics

OPPORTUNITY

Growth in preventive healthcare programs

Preventive treatment programs are creating new opportunities in the Antihelminthics Market. Around 46% of regional health campaigns now include parasite screening or deworming support. Nearly 34% of public clinics are expanding access to essential antihelminthic medicines, while school outreach programs continue to improve treatment coverage.

DRIVERS

Rising demand for human and animal parasite control

Growing awareness of parasite management is a major market driver. Around 51% of livestock farms now use routine deworming schedules. Nearly 38% of household pet owners follow regular parasite prevention plans, while community health demand remains steady in endemic zones.

RESTRAINTS

"Drug resistance and repeated treatment limits"

The Antihelminthics Market faces pressure from resistance concerns in both human and veterinary use. Around 29% of livestock users report reduced response after repeated use of the same treatment class. Nearly 24% of health programs now rotate medicines to maintain effectiveness.

CHALLENGE

"Distribution gaps in remote areas"

Access remains a challenge in underserved locations. Around 33% of rural communities face irregular medicine supply. Nearly 26% of outreach programs report delays in last-mile delivery, storage, or follow-up monitoring, which can reduce treatment continuity and patient adherence.

Segmentation Analysis

Global Antihelminthics Market size was USD 1.97 Billion in 2025 and is projected to touch USD 2.14 Billion in 2026, rise to USD 2.31 Billion in 2027, and reach USD 4.38 Billion by 2035, exhibiting a CAGR of 8.3% during the forecast period (2026-2035). The market is segmented by disease indication and drug class. Growth is supported by preventive healthcare programs, animal health demand, and wider treatment access in parasite-prone regions.

By Type

Schistosomiasis

Schistosomiasis remains a major segment because treatment programs in endemic regions require recurring large-scale medicine supply. Around 36% of public parasite control budgets in affected regions are directed toward schistosomiasis management and prevention.

Schistosomiasis held the largest share in the Antihelminthics Market, accounting for USD 0.56 Billion in 2026, representing 26% of the total market. This segment is expected to grow at a CAGR of 8.52% from 2026 to 2035.

Fasciolasis

Fasciolasis demand is supported by both human and livestock treatment needs, especially in agricultural economies. Nearly 18% of veterinary parasite spending in some livestock regions relates to fluke control programs.

Fasciolasis accounted for USD 0.36 Billion in 2026, representing 17% of the total market. This segment is expected to grow at a CAGR of 8.11% from 2026 to 2035.

Filariasis

Filariasis treatment remains important in tropical public health campaigns. Around 22% of community-based parasite treatment drives include medicines linked to filariasis control in affected areas.

Filariasis accounted for USD 0.41 Billion in 2026, representing 19% of the total market. This segment is expected to grow at a CAGR of 8.43% from 2026 to 2035.

Angiostrongylosis

Angiostrongylosis is a smaller but clinically relevant segment, especially in specific geographies with exposure risks. Specialized diagnosis growth is supporting more targeted treatment demand.

Angiostrongylosis accounted for USD 0.19 Billion in 2026, representing 9% of the total market. This segment is expected to grow at a CAGR of 7.92% from 2026 to 2035.

Ascariasis

Ascariasis remains common in school-age deworming programs and sanitation-linked health campaigns. Nearly 31% of child-focused deworming volumes in selected regions address roundworm infections.

Ascariasis accounted for USD 0.34 Billion in 2026, representing 16% of the total market. This segment is expected to grow at a CAGR of 8.27% from 2026 to 2035.

Giardiasis

Giardiasis treatment demand is supported by water hygiene concerns and pediatric care needs. Around 14% of gastrointestinal parasite prescriptions in some outpatient settings relate to giardiasis treatment.

Giardiasis accounted for USD 0.17 Billion in 2026, representing 8% of the total market. This segment is expected to grow at a CAGR of 8.05% from 2026 to 2035.

Other

Other parasitic conditions include niche and regional infections requiring targeted antihelminthic therapy through hospitals, specialty clinics, and veterinary channels.

Other accounted for USD 0.11 Billion in 2026, representing 5% of the total market. This segment is expected to grow at a CAGR of 7.74% from 2026 to 2035.

By Application

Benzimidazoles

Benzimidazoles lead the market because of broad-spectrum activity, routine deworming use, and availability across public and private channels. Around 47% of common intestinal parasite treatments use this class.

Benzimidazoles held the largest share, accounting for USD 0.79 Billion in 2026, representing 37% of the total market. This segment is expected to grow at a CAGR of 8.44% from 2026 to 2035.

Abamectin

Abamectin is widely used in veterinary applications and selected parasite control programs where strong efficacy is required in animal health management.

Abamectin accounted for USD 0.36 Billion in 2026, representing 17% of the total market. This segment is expected to grow at a CAGR of 8.09% from 2026 to 2035.

Salicylanilides

Salicylanilides remain important in livestock fluke control and targeted veterinary treatment protocols across farm sectors.

Salicylanilides accounted for USD 0.26 Billion in 2026, representing 12% of the total market. This segment is expected to grow at a CAGR of 7.96% from 2026 to 2035.

Praziquantel

Praziquantel is a core medicine for schistosomiasis and tapeworm-related treatment programs, especially in public health campaigns.

Praziquantel accounted for USD 0.51 Billion in 2026, representing 24% of the total market. This segment is expected to grow at a CAGR of 8.37% from 2026 to 2035.

Other

Other drug classes include combination therapies and specialized products used in hospital or veterinary settings.

Other accounted for USD 0.22 Billion in 2026, representing 10% of the total market. This segment is expected to grow at a CAGR of 7.88% from 2026 to 2035.

Antihelminthics Market Regional Outlook

Global Antihelminthics Market size was USD 1.97 Billion in 2025 and is projected to touch USD 2.14 Billion in 2026, rise to USD 2.31 Billion in 2027, and reach USD 4.38 Billion by 2035, exhibiting a CAGR of 8.3% during the forecast period (2026-2035). Regional demand is driven by public health deworming campaigns, livestock parasite control, companion animal care, and broader access to essential medicines. High-burden regions lead treatment volume, while developed markets support branded therapies and veterinary demand.

North America

North America remains a stable Antihelminthics Market supported by pet healthcare spending, livestock management, and imported travel-related treatment demand. Around 49% of companion animal clinics recommend scheduled deworming protocols. Nearly 37% of cattle and sheep operations use routine parasite control products to improve herd productivity and reduce seasonal infection risks.

North America held a market size of USD 0.47 Billion in 2026, representing 22% of the total market. This region is expected to grow at a CAGR of 7.84% from 2026 to 2035, driven by veterinary demand, preventive care, and established pharmaceutical distribution networks.

Europe

Europe has strong demand through regulated livestock farming, pet ownership growth, and healthcare awareness. Around 43% of veterinary parasite treatments in the region are linked to routine intestinal worm control. Nearly 29% of selected healthcare centers stock antihelminthic medicines for imported or travel-associated parasitic infections.

Europe accounted for USD 0.43 Billion in 2026, representing 20% of the total market. This region is expected to grow at a CAGR of 7.66% from 2026 to 2035, supported by animal health spending and preventive treatment programs.

Asia-Pacific

Asia-Pacific leads the Antihelminthics Market because of large population size, tropical disease burden, rural healthcare needs, and major livestock industries. Around 52% of community deworming drives in high-need areas are located in this region. Nearly 41% of poultry and farm animal parasite treatment demand also comes from Asia-Pacific markets.

Asia-Pacific held the largest market size of USD 0.86 Billion in 2026, representing 40% of the total market. This region is expected to grow at a CAGR of 8.91% from 2026 to 2035, driven by public health campaigns, veterinary expansion, and wider medicine access.

Middle East & Africa

Middle East & Africa is growing steadily through sanitation programs, NGO-supported treatment drives, and rising veterinary service access. Around 34% of public parasite treatment volumes in selected countries are linked to outreach campaigns. Nearly 26% of livestock farms now use more regular deworming schedules than previous years.

Middle East & Africa accounted for USD 0.38 Billion in 2026, representing 18% of the total market. This region is expected to grow at a CAGR of 8.27% from 2026 to 2035, supported by disease control initiatives, animal health demand, and expanding rural supply chains.

List of Key Antihelminthics Market Companies Profiled

Investment Analysis and Opportunities in Antihelminthics Market

Investment in the Antihelminthics Market is rising as governments and private healthcare groups focus on preventive treatment and animal health productivity. Around 44% of new spending is directed toward generic medicine manufacturing and supply security. Nearly 36% of investors prefer companies with strong veterinary portfolios because recurring demand is stable. About 31% of healthcare procurement budgets in affected regions now include deworming medicines. Asia-Pacific attracts close to 39% of fresh investment due to high treatment volume and population needs. Around 27% of market opportunities come from companion animal care, while 24% come from livestock productivity programs. Nearly 22% of buyers now seek child-friendly dosage formats. Partnerships with NGOs and public agencies also create room for expansion, with 29% of tenders favoring large-scale supply capability.

New Products Development

New Products Development in the Antihelminthics Market is focused on better compliance, combination therapy, and easier dosing. Around 41% of recent launches include chewable tablets, flavored suspensions, or dispersible formats. Nearly 33% of product updates now target pediatric use with simpler dose guidance. About 28% of new veterinary products combine multi-parasite coverage in one treatment cycle. Long-shelf-life packaging appears in almost 26% of recent launches for tropical storage conditions. Around 21% of innovation programs focus on resistance management through combination formulas. Improved blister packaging and single-dose convenience have grown by nearly 19%. Manufacturers are also investing in faster registration pathways for essential medicines across emerging markets.

Recent Developments

• Sanofi Supply Expansion: In 2025, the company improved essential medicine distribution capacity by nearly 24%, helping support wider treatment campaign availability.
• Bayer Veterinary Update: In 2025, new animal parasite products improved multi-worm treatment coverage by around 18% for farm users.
• Pfizer Packaging Launch: In 2025, easier-dose packaging reduced administration errors by nearly 16% in selected pharmacy channels.
• Merck & Co. Production Upgrade: In 2025, manufacturing improvements increased tablet output efficiency by about 21% for core treatments.
• Abbott Pediatric Format Release: In 2025, child-friendly suspension formats improved caregiver acceptance by nearly 19% in target markets.

Report Coverage

This report provides a full study of the Antihelminthics Market across disease indications, drug classes, regional trends, competition, and future opportunities. It covers Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis, and other parasitic conditions that require routine or targeted treatment.

The report also reviews product categories including Benzimidazoles, Abamectin, Salicylanilides, Praziquantel, and other formulations. Benzimidazoles hold 37% share due to broad-spectrum use, while Praziquantel accounts for 24% through strong demand in schistosomiasis programs. Veterinary-focused classes also maintain stable demand through livestock and pet treatment channels.

Regional analysis includes Asia-Pacific with 40% share, North America with 22%, Europe with 20%, and Middle East & Africa with 18%. Around 46% of buyers prioritize affordability, while 34% focus on broad-spectrum efficacy and 28% seek easy dosing formats. The report also examines procurement models, public health tenders, generic competition, supply chain trends, resistance concerns, and future demand linked to sanitation programs, veterinary care, and preventive medicine access.

Antihelminthics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1.97 Billion in 2026
Market Size Value By	USD 4.38 Billion by 2035
Growth Rate	CAGR of 8.3% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Schistosomiasis Fasciolasis Filariasis Angiostrongylosis Ascariasis Giardiasis Other By Application : Benzimidazoles Abamectin Salicylanilides Praziquantel Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Antihelminthics Market expected to touch by 2035?

  The global Antihelminthics Market is expected to reach USD 4.38 Billion by 2035.

• What CAGR is the Antihelminthics Market expected to exhibit by 2035?

  The Antihelminthics Market is expected to exhibit a CAGR of 8.3% by 2035.

• Who are the top players in the Antihelminthics Market?

  Abbott, Novartis, ZEISS International, Johnson & Johnson, Sanofi, Merck & Co., GlaxoSmithKline, Astellas Pharma, Bayer, Mentis Pharma, Pfizer, ALLERGAN, AstraZeneca

• What was the value of the Antihelminthics Market in 2025?

  In 2025, the Antihelminthics Market value stood at USD 1.97 Billion.

Related Reports

Gaucher Disease Drugs Market Extraoral X-Ray System Market Veterinary Endoscopy Market Eloctate Market High Frequency Ventilators Market Vein Strippers Market